Shinva Medical Instrument Co.Ltd(600587) it was announced on December 24 that the company recently received the registration certificate of medical devices of the people’s Republic of China issued by Shandong Provincial Drug Administration, and the eluent for glycosylated hemoglobin analysis (HPLC) of the company’s products was approved for listing.
The main feature of the product is that the eluent (HLA) is used in conjunction with glycosylated hemoglobin analyzer. The ion exchange high pressure liquid chromatography is used to detect the content of glycosylated hemoglobin in whole blood in vitro. It is an effective index for screening, diagnosing, controlling blood sugar and evaluating the curative effect of the whole blood. It has high accuracy and good repeatability.
The company said that the approval and listing of glycosylated hemoglobin analysis eluent (high performance liquid chromatography) has improved the glycosylated hemoglobin detection platform, further enriched the company’s in vitro diagnosis product line, helped to improve the company’s core competitiveness and had a positive impact on the company’s future operation.
(China Securities Journal · China Securities Network)
